preparing a compound 4, namely, taking the compound 2 as the initial raw material,carrying out modification of GLP-1 (9-37) end amino by a compound 3, and then carrying out a liquid phase acylation coupling reaction with a reaction condensing agent and alkali to obtain a compound4
Deciding if GLP-1 medications are suitable for you involves an evaluation with a medical provider
This dual approach is a key factor in why tirzepatide might be a particularly effective treatment option for some individuals
In some cases, a live video consultation may be required before prescription approval
Embodiment 3 [0053] Expression and purification of embodiment 3 fusion protein [0054] Transfer the seed liquid of the recombinant positive engineering strain of Example 2 to LB medium according to the inoculum size of 2%, cultivate it at 37C until OD600=0.6, add 50 l of 0.5mol / L IPTG, induce at 15C for 16 hours, and collect by centrifugation For each 1 g of wet bacteria, resuspend in 10 mL of lysis buffer (50 mM Tris-HCl, 50 mM NaCl, 5% glycerol, pH 8.0, 17 l (10 mg / mL PMSF)), ultrasonicate and centrifuge to obtain supernatant and precipitate
Notable exclusions include antibodies, label expansion, biosimilars